IN2014DN09805A - - Google Patents

Info

Publication number
IN2014DN09805A
IN2014DN09805A IN9805DEN2014A IN2014DN09805A IN 2014DN09805 A IN2014DN09805 A IN 2014DN09805A IN 9805DEN2014 A IN9805DEN2014 A IN 9805DEN2014A IN 2014DN09805 A IN2014DN09805 A IN 2014DN09805A
Authority
IN
India
Prior art keywords
disorders
oxy133
bioactive
pharmaceutical composition
compound
Prior art date
Application number
Inventor
Farhad Parhami
Michael E Jung
Frank Stappenbeck
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2014DN09805A publication Critical patent/IN2014DN09805A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates ,e.g.,to a synthetic compound , Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders , including e.g. bone disorders , obesity ,cardiovascular disorders , and neurological disorders.
IN9805DEN2014 2012-05-07 2014-11-19 IN2014DN09805A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643746P 2012-05-07 2012-05-07
PCT/US2013/032693 WO2013169399A1 (en) 2012-05-07 2013-03-15 Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis

Publications (1)

Publication Number Publication Date
IN2014DN09805A true IN2014DN09805A (en) 2015-07-31

Family

ID=49551140

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9805DEN2014 IN2014DN09805A (en) 2012-05-07 2014-11-19

Country Status (11)

Country Link
US (1) US9717742B2 (en)
EP (1) EP2847206A4 (en)
JP (1) JP6262723B2 (en)
KR (1) KR20150013232A (en)
CN (1) CN104395331B (en)
AU (1) AU2013260059B2 (en)
CA (1) CA2872751A1 (en)
HK (1) HK1207649A1 (en)
IN (1) IN2014DN09805A (en)
RU (1) RU2632191C2 (en)
WO (1) WO2013169399A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
CA2707663C (en) 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
AU2015252859B2 (en) * 2014-05-02 2019-11-07 The Regents Of The University Of California Bone-selective osteogenic oxysterol bisphosphonate analogs
WO2016094421A1 (en) 2014-12-09 2016-06-16 Warsaw Orthopedic, Inc. Compounds and methods involving sterols
EP3310372A4 (en) * 2015-05-19 2019-03-06 Mayo Foundation For Medical Education And Research Methods and materials for promoting bone formation
US10632230B2 (en) * 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9877836B2 (en) * 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9878070B2 (en) * 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
EP3834816A1 (en) 2015-06-17 2021-06-16 Warsaw Orthopedic, Inc. Implants including an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
AU2016347052B2 (en) * 2015-10-27 2021-03-25 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US11090411B2 (en) 2016-01-28 2021-08-17 Warsaw Orthopedic, Inc. Electron beam irradiated osteoinductive bone implant
US9987290B2 (en) 2016-03-28 2018-06-05 Warsaw Orthopedic, Inc. Methods for the separation and detection of an oxysterol
US20170275330A1 (en) * 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CN105924493A (en) * 2016-04-23 2016-09-07 何华琼 Bucinnazine hydrochloride medicinal composition and application thereof in biomedicines
US10688222B2 (en) * 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) * 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
WO2019048898A1 (en) 2017-09-05 2019-03-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of endothelial dysfunction
KR102283508B1 (en) * 2020-04-17 2021-07-29 가톨릭대학교 산학협력단 Composition for Facilitating Osteogenic Differentiation of Stem Cell Spheroids Comprising Bone Morphogenetic Protein-2 As Active Ingredient
US20230166003A1 (en) * 2021-11-24 2023-06-01 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB869007A (en) 1956-10-03 1961-05-25 Ciba Ltd New heterocyclically substituted steroids
CH433275A (en) 1963-07-09 1967-04-15 Hoffmann La Roche Process for the preparation of 19-alkyl steroids
JPS5111114B1 (en) 1969-03-14 1976-04-08
US3887545A (en) 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
LU87201A1 (en) 1988-04-14 1989-11-14 Cird ANTHRALINE AND STEROL-BASED COMPLEXES, THEIR PROCESS FOR OBTAINING AND THEIR USE IN THERAPEUTICS AND COSMETICS
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
JPH09507741A (en) 1992-06-10 1997-08-12 アメリカ合衆国 Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2705361B1 (en) 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
DE69433592T2 (en) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle THE ACHIEVEMENT OF HIGH TITERS OF THE RECOMBINANT AAV VECTOR
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
WO1995018821A2 (en) 1994-01-06 1995-07-13 Sri International Novel antiandrogenic agents and related pharmaceutical compositions and methods of use
CA2250874A1 (en) 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
CA2251983C (en) 1996-04-19 2003-12-16 Sudhakar Kadiyala Regeneration and augmentation of bone using mesenchymal stem cells
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US5840752A (en) 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
US6080779A (en) 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
BR9806989A (en) 1997-01-24 2000-03-14 Univ California Process for treating the epidermis or mucous membrane of a mammalian individual.
KR20010012643A (en) 1997-05-16 2001-02-26 에프.지.엠. 헤르만스 20-ARALKYL-5α-PREGNANE DERIVATIVES
DE19723794A1 (en) 1997-06-06 1998-12-10 Jenapharm Gmbh Non-estrogenic derivatives of estradiol with antioxidant activity
US5929062A (en) 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
CA2323448A1 (en) 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption
EP0943332A1 (en) 1998-03-19 1999-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Prevention and treatment of adhesions
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
WO2000053618A1 (en) 1999-03-09 2000-09-14 Akzo Nobel N.V. 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
WO2001015676A2 (en) 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US20020115695A1 (en) 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
GB0101933D0 (en) 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
EP1421607A2 (en) 2001-02-12 2004-05-26 ASM America, Inc. Improved process for deposition of semiconductor films
JP2004534743A (en) 2001-04-09 2004-11-18 ロランティス リミテッド Hedgehog
WO2003077869A2 (en) 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Neuroprotective spirostenol pharmaceutical compositions
EP1556057A4 (en) 2002-08-29 2009-07-15 Univ California Agents and methods for enhancing bone formation
DE10307104A1 (en) 2003-02-19 2004-09-23 Schering Ag Anti-tumor effective 2-substituted Estra-1,3,5 (10) -trien-3-yl sulfamate
BRPI0412439A (en) * 2003-07-09 2006-09-05 Forbes Medi Tech Inc compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions.
WO2005028616A2 (en) 2003-07-24 2005-03-31 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and methods of use thereof to treat heart disorders
AU2004267067A1 (en) 2003-08-18 2005-03-03 Wyeth Human LXR alpha variants
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1697300A4 (en) 2003-12-24 2007-10-03 Univ Louisville Res Found Bone targeting compounds for delivering agents to the bone for interaction therewith
AU2005254949A1 (en) 2004-06-10 2005-12-29 Merck & Co., Inc. Estrogen receptor modulators
EP1781779A2 (en) 2004-08-02 2007-05-09 Novozymes A/S Creation of diversity in polypeptides
DE102004042822A1 (en) 2004-08-31 2006-03-16 Technische Universität Dresden Compounds and methods of treatment, diagnosis and prognosis in pancreatic diseases
US20090202660A1 (en) 2005-04-07 2009-08-13 The Regents Of The University Of California Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation
JP2009512422A (en) 2005-09-02 2009-03-26 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア Osteogenic and anti-adipogenic oxysterols
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
US20100048944A1 (en) 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
US20080070883A1 (en) 2006-09-19 2008-03-20 Wyeth Use of LXR modulators for the prevention and treatment of skin aging
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
AU2007339325A1 (en) 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
US8071575B2 (en) 2007-02-23 2011-12-06 University Of Louisville Research Foundation Methods and compounds for the targeted delivery of agents to bone for interaction therewith
US20080221070A1 (en) 2007-03-06 2008-09-11 Pierce William M Methods and compounds for the targeted delivery of agents to bone for interaction therewith
US20100112030A1 (en) 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
CA2707663C (en) * 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
MY163799A (en) 2008-02-07 2017-10-24 Dsg Tech Holdings Limited Method of making an absorbent composite and absorbent articles employing the same
WO2011006087A1 (en) 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
US20120309730A1 (en) 2010-02-16 2012-12-06 The Johns Hopkins University Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2012024581A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024584A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2013169397A1 (en) 2012-05-07 2013-11-14 The Regents Of The University Of California Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
AU2015252859B2 (en) 2014-05-02 2019-11-07 The Regents Of The University Of California Bone-selective osteogenic oxysterol bisphosphonate analogs

Also Published As

Publication number Publication date
RU2632191C2 (en) 2017-10-03
EP2847206A4 (en) 2016-01-20
JP6262723B2 (en) 2018-01-17
AU2013260059A1 (en) 2014-11-27
WO2013169399A1 (en) 2013-11-14
CN104395331B (en) 2016-11-02
EP2847206A1 (en) 2015-03-18
RU2014149164A (en) 2016-07-10
KR20150013232A (en) 2015-02-04
HK1207649A1 (en) 2016-02-05
CN104395331A (en) 2015-03-04
AU2013260059B2 (en) 2017-05-18
US20150118277A1 (en) 2015-04-30
CA2872751A1 (en) 2013-11-14
JP2015518493A (en) 2015-07-02
US9717742B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
IN2014DN09805A (en)
IN2014DN09804A (en)
MX2020012825A (en) Multicyclic compounds and methods of use thereof.
MX345535B (en) Partially saturated tricyclic compounds and methods of making and using same.
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
UA115136C2 (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
MD20150023A2 (en) Novel bicyclic pyridinones
MD20150091A2 (en) Anti-viral compounds
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
MX343135B (en) Fumagillol type compounds and methods of making and using same.
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
MX342257B (en) Oxaspiro [2.5] octane derivatives and analogs.
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
MX2012001134A (en) Compositions and methods for inhibition of the jak pathway.
MX370253B (en) Compositions of jasmonate compounds and methods of use.
WO2013040227A3 (en) Therapeutic compounds
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.